Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OERIS
- Development stage
- Unknown
- Lead developer
- Shilpa Medicare
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
OERIS is an extended-release injectable suspension of ondansetron, a selective 5-HT3 receptor antagonist, developed by Shilpa Medicare Limited. It is designed as a single-dose intramuscular injection to provide prophylaxis against both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV) for up to five days. By utilizing a novel drug-delivery system, OERIS aims to eliminate the need for multiple daily doses or oral follow-up medications typically required with standard ondansetron formulations. In Phase 3 clinical trials, it demonstrated a superior complete response rate of 89% compared to 82% for standard ondansetron, while maintaining a favorable safety profile with no serious adverse events reported.
- Brand names
- OERIS
- Other names
- Ondansetron Extended Release Injectable Suspension
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on OERIS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OERIS.